Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05850-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Boris Kubuschok und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II (Hematology/Oncology) and Comprehensive Cancer Center Augsburg, CCC Alliance WERA and Bavarian Cancer Research Cen…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Rituximab, Quality of Life. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Augsburg.
Abstract (Originalsprache)
Health-related quality of life (HRQoL) data are important indicators of health status in patients with lymphoma. The objective of this analysis was to assess the impact of treatment with Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL in treatment-naïve adult patients with diffuse large B-cell lymphoma (DLBCL) included in the prospective, real-world REFLECT study. REFLECT is the first prospective study to assess HRQoL in patients with DLBCL treated with a rituximab biosimilar. HRQoL was assessed via the patient-reported European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire at baseline, mid-treatment (month 3), end of treatment (month 6), and follow-up (months 9 and 12). Subgroup analyses were performed to evaluate the influence of baseline characteristics on HRQoL, and associations between baseline HRQoL and treatment response. HRQoL was assessed in 169 patients. Mean global health status score remained stable from baseline (54.8) to mid-treatment (month 3; 54.7), before steadily improving through to end of treatment (month 6; 61.4), and follow-up month 9 (64.9) and month 12 (68.8). Similar trends were observed across most functional and symptom subscales. Higher cognitive, physical, or role functioning, and less appetite loss, diarrhea, fatigue, or pain at baseline, were all associated with an improved likelihood of reaching a complete versus partial response at the end of treatment. Overall, these findings confirm the HRQoL benefits of R-CHOP therapy in treatment-naïve adult patients with DLBCL, and suggest that baseline HRQoL may be predictive of treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine II (Hematology/Oncology) and Comprehensive Cancer Center Augsburg, CCC Alliance WERA and Bavarian Cancer Research Center (BZKF), Universitätsklinikum Augsburg, Augsburg, Germany. Boris.Ku…
- Onkologische Praxis Oldenburg, Oldenburg, Germany.
- Comprehensive Cancer Center Mainfranken, Onkologie Aschaffenburg, Germany and Comprehensive Cancer Center Mainfranken, CCC Alliance WERA and BZKF, Würzburg, Germany.
- MVZ Klinikum Osnabrück GmbH, Osnabrück, Germany.
- OncoResearch Lerchenfeld, Hamburg, Germany.
- Department of Medicine A for Hematology, Oncology and Pneumology, Universitätsklinikum Münster, Münster, Germany.
Förderung
- Universitätsklinikum Augsburg
Zitieren
APA
Kubuschok, B., Otremba, B., Welslau, M., Topaly, J., Wolff, T., Lenz, G., Grau, M., Bittencourt da Silva, L., Brückmann, I., & Foierl, T. (2024). Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP. Annals of Hematology. https://doi.org/10.1007/s00277-024-05850-5
Vancouver
Kubuschok B, Otremba B, Welslau M, Topaly J, Wolff T, Lenz G, et al. Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP. Annals of Hematology. 2024. doi:10.1007/s00277-024-05850-5
BibTeX
@article{Kubuschok2024,
author = {Kubuschok, Boris and Otremba, Burkhard and Welslau, Manfred and Topaly, Julian and Wolff, Thomas and Lenz, Georg and Grau, Michael and Bittencourt da Silva, Larissa and Brückmann, Ines and Foierl, Tobias},
title = {Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05850-5}
}
EUVIMED